Squarepoint’s Definium Therapeutics DFTX Stock Holding History

Squarepoint’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-13,300	Closed	-$92.6K	–	5111
2024 Q4	$92.6K	Buy	+13,300	New	+$91.5K	﹤0.01%	4718

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Squarepoint's DFTX Position: Q2 2026 in Review

Squarepoint sold out of Definium Therapeutics (DFTX) in Q2 2026, closing a stake of 125,522 shares — an estimated $2.37M sold.

Squarepoint first reported a position in DFTX in Q3 2021 and held it in 11 quarters. The position peaked at $2.37M in Q1 2026. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Squarepoint reported no remaining Definium Therapeutics position as of Q2 2026 after selling out during the quarter.
Squarepoint sold 125,522 Definium Therapeutics shares in Q2 2026, an estimated $2.37M.
Squarepoint first reported a position in Definium Therapeutics in Q3 2021 and held it in 11 quarters.
Squarepoint's Definium Therapeutics position peaked at $2.37M in Q1 2026.
362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.